Management of Leukocytosis and Thrombocytosis

Diagnostic Approach

• The National Comprehensive Cancer Network recommends confirming diagnosis of chronic myeloid leukemia (CML) with fluorescence in situ hybridization (FISH) on peripheral blood using dual probes for BCR and ABL genes 1

Risk Assessment

• The National Comprehensive Cancer Network evaluates risk factors for thromboembolic disease, including age >60 years, prior history of thrombosis, and cardiovascular risk factors 4, 5
• The National Comprehensive Cancer Network also considers the degree of thrombocytosis (platelet count >1,000 x 10^9/L) as a risk factor for bleeding 6

Management Algorithm for Symptomatic Leukocytosis

• The National Comprehensive Cancer Network recommends initiating hydroxyurea (2-4g per day) as first-line therapy for significant leukocytosis (WBC >30,000/μL) with symptoms 7
• The National Comprehensive Cancer Network suggests considering apheresis for severe symptoms of leukostasis 1, 3
• For CML, the National Comprehensive Cancer Network prefers tyrosine kinase inhibitors like imatinib 1, 8

Management Algorithm for Symptomatic Thrombocytosis

• The National Comprehensive Cancer Network recommends hydroxyurea as first-line therapy for symptomatic thrombocytosis 1, 3, 6
• The National Comprehensive Cancer Network suggests considering anagrelide as second-line therapy for essential thrombocythemia (ET) 6
• The National Comprehensive Cancer Network recommends apheresis for extreme thrombocytosis with acute symptoms 1, 3

Special Considerations

• The National Comprehensive Cancer Network monitors BCR-ABL transcript levels every 3 months during treatment in CML patients 1
• The National Comprehensive Cancer Network prefers interferons (alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) over hydroxyurea for pregnant patients 4, 5
• The National Comprehensive Cancer Network considers cytoreductive therapy for extreme thrombocytosis (>1,500 x 10^9/L) due to increased bleeding risk 6

Monitoring Response to Treatment

• The National Comprehensive Cancer Network defines complete hematologic response criteria, including leukocyte count <10 x 10^9/L, platelet count <450 x 10^9/L, and no immature cells in peripheral blood 8

Dose Adjustments and Management of Side Effects

• The National Comprehensive Cancer Network recommends holding drug until ANC ≥1500/mm^3, then resuming at reduced dose for Grade 3-4 neutropenia (ANC <1000/mm^3) 1
• The National Comprehensive Cancer Network suggests using growth factors in combination with therapy for resistant cytopenias 1, 8